Researchers at the Hubrecht Institute and the University Medical Center (UMC) Utrecht successfully developed a culturing system for human liver stem cells as well as stem cells from pancreatic cancer. They describe the development of these culturing systems in two articles in this week’s edition of Cell magazine.
Scientists from the German Cancer Research Center in Heidelberg and from the Medical Faculty Mannheim of Heidelberg University treated mice with a combination of a low-dose metronomic chemotherapy and an antibody against Ang-2, a regulatory protein of the blood vessel lining cells. The treated animals had significantly less metastases.
Radiotherapy always encounters particular challenges when a tumour is ‘mobile’. This is when radiotherapy must be carried out over several weeks. Within that period the tumour position, shape and expansion typically will keep changing. Thus radiotherapy needs continuous adaptation to maintain continuously precise radiation. Report: Chrissanthi Nikolakudi
The treatment of cerebral aneurysms is often very complex and initially it is not always obvious which type of treatment is best suited for an individual case. In October, during the Annual Congress of the German Society for Neuroradiology e.V., a working group from Hamburg introduced a procedure that enables the production of exact copies of individual aneurysms with a 3D printer.
The number of cancer patients in Germany continues to rise steadily. An increase in the number of newly diagnosed cases of 14% is expected by 2020 compared to 2008. Therefore early detection is increasingly the focus of attention.
In studies on prostate cancer, scientists from the German Cancer Research Center (DKFZ) simultaneously investigated the genetic and epigenetic development of the tumors.
Over the next few years, the University Medical Center (UMC) Utrecht and Quirem Medical will be working closely together to maximize the benefits of using holmium microspheres to treat liver cancer patients worldwide.
A small prick to sample blood instead of complex pathological or other diagnostic procedures – this is how early cancer diagnosis will be in the near future. Blood tests to diagnose tumorous diseases early are already being researched for clinical use.
Ultrasound technology is continuously developing and competing with the sectional imaging procedures – therapy progress can be monitored, facilitating personalised medicine.
New imaging biomarkers are helping radiology to play a greater role in new drug developments.
‘The disease “cancer” is increasingly classified into sub-groups. Today, we are already dealing with a number of orphan diseases,’ says Professor Richard Greil MD, head of LIMCR at University Hospital Salzburg.
In a review article published Feb. 14 in The Lancet Oncology, Johns Hopkins experts identify three major sources of high cancer costs and argue that cancer doctors can likely reduce them without harm to patients.
Curie-Cancer, the body which leads the Institut Curie's industry partner research activity, and Servier, today announce that they have renewed their partnership with the aim of identifying therapeutic targets for treating ‘triple negative’ breast cancers. The partnership will continue for a further three years.
The “State of Oncology 2013” report by the International Prevention Research Institute [IPRI] warns that the global number of new cancer cases will have doubled between 2008 and 2030.
Partnerships are at the top of the agenda for RSNA 2013. To meet current and emerging challenges, “we need internal partnerships within radiology and external ones with our clinical peers as well as with our patients,” outlined Sarah S. Donaldson, MD in her opening address of the 99th RSNA Scientific Assembly and Annual Meeting.
Healthcare is undergoing a major change set to offer a real prospect of far more genetically targeted treatments, according a leading human geneticist Sir John Burn, Professor of Clinical Genetics at Newcastle University, England.
It looks like a drug, it is injected in patients like a drug, but its acts like a medical device. Welcome to the new world of nanomedicine.
Along with others, Germany has unanimously welcomed the revision of the EU directive on clinical trials. The change from mere guideline into a regulation valid in all member states, specifically aimed at making it easier to carry out multinational studies, is particularly welcomed, Bettina Döbereiner reports
In the country’s first scientific study to correlate the demographic changes and frequency of tumorous diseases, demographic changes have led scientists to forecast a significant increase in the number of cancerous diseases in coming years.
Cancer diagnostics - Nanotechnology is currently being used in oncology to improve early tumour detection, imaging procedures and targeting of cancer therapies. Cancer biomarkers, indicators that are being produced by the body in spreading tumour cells, play an important role in cancer detection, Dr. Jörg Raach reports
Scientists at Imperial College in London, United Kingdom, have developed an ‘intelligent knife’ that instantly informs surgeons whether the tissue they are operating on is cancerous.
Multidisciplinary tumour boards (MDTs) are widespread in the Netherlands, and ‘they tend to be proliferating lately,’ according to Professor Folkert van Kemenade, Chair of the Pathology department at the VU University Medical Centre in Amsterdam.
At Bracco Suisse SA in Geneva all efforts are dedicated to contrast media for ultrasound scans. During their visit to the firm’s research centre and manufacturing site, Daniela Zimmermann and Ralf Mateblowski met with François Tranquart MD PhD, general manager of the Bracco Suisse research centre, to hear why SonoVue is now Europe’s most popular ultrasound contrast agent, with research…
Like any other cancer – breast cancer is a highly individual disease, shaped by many factors such as age, health status or genetics. Due to the complex web of molecular pathological processes and resistance mechanisms it is very difficult to select the most effective therapy for each patient.
A 2012 study analysing the care of cancer patients in the USA in 138 Veterans’ Administration hospitals (pub: Journal of the National Cancer Institute) questions the effectiveness of tumour board review. The study measured effectiveness by comparing the presence of tumour review boards with stage-specific quality of care and patient outcomes.